Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1-EU clears plans by drugmakers GSK and Novartis to trade assets

      Headlines

      Wed, 28 Jan 2015

      * Large companies try to focus on leading businesses (Recasts with oncology business, adds details)

    2. BRIEF-EU clears GSK- Novartis three-part deal with conditions

      Headlines

      Wed, 28 Jan 2015

      * Received clearance from European Commission of its proposed three-part transaction with Novartis

    3. RPT-EU clears GSK's acquisition of Novartis vaccines with conditions

      Headlines

      Wed, 28 Jan 2015

      BRUSSELS, Jan 28 (Reuters) - The European Commission said on Wednesday it had approved drugmaker GlaxoSmithKline's acquisition of Novartis ' vaccines business, as well as a consumer healthcare joint venture between the two.

    4. EU clears GSK's acquisition of Novartis vaccines with conditions

      Headlines

      Wed, 28 Jan 2015

      BRUSSELS, Jan 28 (Reuters) - The European Commission said on Wednesday it had approved drugmaker GlaxoSmithKline's acquisition of Novartis ' vaccines business, as well as a consumer healthcare joint venture between the two.

    5. EU clears Novartis to buy GSK's oncology business with conditions

      Headlines

      Wed, 28 Jan 2015

      BRUSSELS, Jan 28 (Reuters) - The European Commission said on Wednesday it had cleared the acquisition by Novartis of GSK oncology business subject to conditions.

    6. Amgen's Biosimilar Headwinds Poised to Increase in 2015, but We're Bullish on Upcoming Launches

      Commentary

      Wed, 28 Jan 2015

      key neutropenia product from U.S. biosimilar competition (which could arrive by the end of the year). However, Novartis ' Zarxio is poised to launch this year as another competitor to Neupogen, and Hospira has filed for approval of a biosimilar

    7. Novartis pharma boss expects pressure on cancer drug prices

      Headlines

      Tue, 27 Jan 2015

      ZURICH, Jan 27 (Reuters) - Payers are likely to put pressure on drugmakers to lower the cost of cancer medicines, particularly when alternative treatments are available, the head of Novartis ' pharma division said on Tuesday.

    8. UPDATE 3- Novartis flags faster sales and profit growth for 2015

      Headlines

      Tue, 27 Jan 2015

      * Shares rise 1.6 percent, outperform sector (Updates shares, adds link to CEO's comments on costs in Davos)

    9. BRIEF- Novartis eyes procurement savings of at least $1.6 bln in 2015

      Headlines

      Tue, 27 Jan 2015

      * Novartis CEO expects savings from procurement to be at or greater than the $1.6 billion achieved in 2014 Further company coverage: (Reporting By Caroline Copley)

    10. Novartis Posts Modest 4Q, but Strong 2015 Guidance and Pipeline Progress Set Up Solid Outlook

      Commentary

      Tue, 27 Jan 2015

      ADR) fair value estimates for Novartis , as fourth-quarter results fell ..... consumer joint venture), we expect Novartis will post stronger margins and have ..... into Phase III studies could help Novartis defend its multi-billion-dollar

    « Prev12345Next »
    Content Partners